Author’s response to reviews

Title: Chronic Obstructive Pulmonary Disease, Bronchial Asthma and Allergic Rhinitis in the adult population within the Commonwealth of Independent States: Rationale and design of the CORE study.

Authors:

Yuriy Feshchenko (admin@ifp.kiev.ua)
Liudmila Yashina (l.ashyna123@gmail.com)
Damilya Nugmanova (damilya@gmail.com)
Olga Gyrina (study.adonis@gmail.com)
Marina Polyanskaya (polianska@ifp.kiev.ua)
Alexander Markov (alex.markov55@gmail.com)
Maryna Moibenko (Maryna.A.Moibenko@gsk.com)
Janina Makarova (yana.j.makarova@gsk.com)
Luqman Tariq (luqman.l.tariq@gsk.com)
Marcelo Horacio (Marcelo.horacio2@gmail.com)
Eljan Mammadbayov (elcan.m@gmail.com)
Irada Akhundova (akhundova.irada@gmail.com)
Averyan Vasylyev (Averyan.G.Vasylyev@gsk.com)

Version: 3 Date: 21 Jun 2017

Author’s response to reviews:

Dear Collegues,

Thanks a lot for consideration to accept our manuscript for publication and relevant review. We have implemented all required ammendmentes i naccordance with the list below (with our confirmations incorporated).
Best regards,

Yana

1. We notice the order of authors provided on the title page is different from the order listed in the submission data. Please confirm the correct order of authorship and provide the correct order in both the submission system and on the title page.

Thank you for your comment. It was corrected.

2. Please remove any Declarations sections from the title page and the supplementary files, as they are already provided in the Declarations section of the manuscript. These sections include:

- Ethics approval and consent to participate
- Consent to publish
- Availability of data and materials
- Competing interests
- Funding
- Authors' Contributions
- Acknowledgements

Thank you for your comment. Any Declarations sections are removed from the title page.

3. Please provide a Keywords section after your Abstract that includes three to ten keywords representing the main content of the article.

Thank you for your comment. ‘Keywords’ section is added after ‘Abstract’

4. In your Ethics approval section of the Declarations, please include the full name of the ethics committees that approved your study in Azerbaijan and Ukraine, as well as the committee reference numbers if available.
Thank you for your comment. The names of the ethics committees are added for all three countries. Committee reference numbers are not available.

5. In your Funding section, please also state the role of the funding body in the design of the study, the collection, analysis, and interpretation of data, and in writing the manuscript.

Thank you for your comment. Section “Funding” is amended accordingly.

6. Please also remove the following statement from Funding and place it as the last line of your abstract with the heading "Trial Registration": "Study Protocol Summary is disclosed at GSK Clinical Study Register (http://www.gsk-clinicalstudyregister.com/study/116757#ps).”

- Please also include the date the study was registered.

Thank you for your comment. "Trial Registration" section is added as the last line of Abstract with date.

7. In your Authors' contributions section, please note that the individual contributions of each author should be specified. Please be sure to cite each author in this section. We notice some information provided in Acknowledgements can be moved to this section.

Thank you for your comment. Authors' contributions section is corrected accordingly.

8. Please also move the first sentence of Acknowledgements to Authors' contributions.

Thank you for your comment. The first sentence of ‘Acknowledgements’ is moved to ‘Authors' contributions’

9. The Acknowledgements should acknowledge anyone who contributed towards the article who does not meet the criteria for authorship including anyone who provided professional writing services or materials. Therefore, any author contributions should be moved to the Authors' contributions section.

Thank you for your comment. Any author contributions are indicated in the ‘Authors' contributions’ section.
10. Thank you for providing a statement regarding the Availability of data and materials. However, we would like to request that you amend this statement. Submission of a manuscript to a BioMed Central journal implies that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality.

Thank you for your comment. Section “Availability of data and materials” is written according to the recommendations from “Editorial policies”:

“Availability of data and materials statements can take one of the following forms…“ – an appropriate option was chosen.

11. Please edit your Figure Legend section, as we notice portions of it may be mislabeled. For example:

Figure 1 Details of the recruitment phase Figure 2 presents the total number of enrolled participants (overall and by country).

Is Figure 2 in this instance meant to read "Figure 1"? Here is an example of how Figure legends should be formatted:

Figure 3. Liver smear from a 6-week-old embryo (CR length 12 mm). A remarkable cluster of macrophages is seen among primitive erythroblasts (see also Fig. 4). A granuloblast is present at the upper right. H & E, ×1,150. (Scott 1974)

Thank you for your comment. The labeling of figures is corrected. The figure legends are formatted similarly to the example.

12. Please remove your tables from the main manuscript as they are already provided as table files. However, upon removal please cite and indicate where the table should appear at the relevant location in the text file so that the table can be added in the correct place during production.

Thank you for your comment. All tables are removed; the references to the tables and indication for them are present in the text.